Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

How pharma can unlock the potential of influencer marketing

Building a successful campaign around influencer marketing

- PMLiVE

Cancer immunotherapy: What’s on the horizon?

Old and new therapies

- PMLiVE

Ionis and Roche gain PRIME status for Huntingdon’s disease candidate

More good news for Ionis after first drug approval

- PMLiVE

Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka

The latest from pharma, biotech and healthcare

- PMLiVE

Mallinckrodt doses first patient in muscular dystrophy trial

Repurposed drug could help delay decline in muscle function

- PMLiVE

China’s BeiGene raises $903m from Hong Kong IPO

Mammoth debut might have exceeded $1bn but for market jitters

- PMLiVE

Insights from Cannes Lions Health Festival 2018

Key learnings and trends

New ICMJE Guidelines and their Impact on Biotech

Currently, and over the past several years, I have enjoyed working with smaller biotechnology and pharma companies, many of which are looking to bring their first product to market. These...

Porterhouse Medical Group

- PMLiVE

Healthcare Comms round up

JOLT and The Ideas Foundation share talent fund, Ashfield opens new office and The Difference Collective offers charitable services

- PMLiVE

Daily Brief: Karuna raises $42m for novel CNS approach, Chen exits Roche, Orchard gains GSK board member

The latest from pharma, biotech and healthcare

Daiichi Sankyo logo

Daiichi gets breakthrough status for pre-NDA leukaemia drug

Quizartinib could have an advantage over rival drug Rydapt

- PMLiVE

Trust me, I’m from pharma

Chris Ross, with the help of five industry thought leaders, explores how the industry can enhance its public reputation by focusing on making a difference – rather than just making...

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links